Partial
Needs Revision
Patient Risk:
Moderate
Summary
The response captures several on-label safety concepts (myopathy/rhabdomyolysis risk, liver monitoring, hypersensitivity, and key interaction classes) but includes multiple symptom-specific and action-oriented instructions that are not supported by the provided label excerpts (e.g., dark/cola-colored urine cue, several specific liver symptom attributions, 'urgent care' guidance, and timing/generalizations).
Category Scores
Accurate Statements
Lipitor can cause muscle aches or muscle weakness (myopathy), and patients should report unexplained muscle pain, tenderness, or weakness.
Label 5.1 Skeletal Muscle: myopathy defined as muscle aches or muscle weakness; advise reporting promptly unexplained muscle pain, tenderness, or weakness; discontinue if myopathy suspected/diagnosed or markedly elevated CPK.
Rare cases of rhabdomyolysis with acute renal failure have been reported.
Label 5.1 Skeletal Muscle: Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported.
Lipitor can be associated with liver dysfunction, including reports of jaundice.
Label 5.2 Liver Dysfunction: One patient developed jaundice; associated biochemical abnormalities.
Hypersensitivity reactions have been reported, including anaphylaxis and angioneurotic edema.
Label 4.2 Hypersensitivity and 6.2 Postmarketing Experience: reports include anaphylaxis, angioneurotic edema.
The risk of myopathy is increased with concurrent administration of certain drugs that raise atorvastatin levels (e.g., clarithromycin, HIV protease inhibitors, itraconazole; also cyclosporine, fibric acid derivatives, niacin, azole antifungals).
Label 5.1 Skeletal Muscle: increased risk with concurrent administration of specified interacting drugs; Label 7.1 Strong CYP3A4 inhibitors lists examples.
Strong CYP3A4 inhibitors can lead to increased plasma concentrations of atorvastatin.
Label 7.1 Strong Inhibitors of CYP 3A4: increases in plasma concentrations of atorvastatin.
Clinicians may check liver function tests (LFTs) prior to and at 12 weeks following initiation and any dose elevation, and periodically thereafter.
Label 5.2 Liver Dysfunction: recommended timing for liver function tests; periodic thereafter.
Clinicians may check creatine phosphokinase (CPK/CK) in situations concerning muscle injury.
Label 5.1 Skeletal Muscle: CPK determinations may be considered; advises discontinuation if markedly elevated CPK occurs.
Increases or new symptoms during upward dose titration are relevant to monitoring for muscle and liver effects.
Label 5.1 Skeletal Muscle: 'particularly during the initial months' and during periods of upward dosage titration; Label 5.2: LFT testing at 12 weeks following dose elevation.
Unsupported Statements
Lipitor can cause muscle pain, tenderness, weakness, or dark/cola-colored urine that can signal muscle injury.
Label 5.1 in the provided excerpts does not mention dark/cola-colored urine as a described sign. It focuses on muscle pain/tenderness/weakness and CPK elevations, and rhabdomyolysis secondary to myoglobinuria without providing 'dark/cola-colored urine' as an explicit patient cue.
Lipitor can cause signs of liver problems, including unusual tiredness, loss of appetite, upper stomach pain, dark urine, and yellowing of the skin/eyes (jaundice).
The provided label excerpts support biochemical abnormalities and an example of jaundice, but do not support the additional specific symptom list (unusual tiredness, loss of appetite, upper stomach pain, dark urine).
Some people notice mild muscle aches after starting a statin that do not come with weakness or dark urine.
The provided label excerpts describe myopathy as muscle aches or muscle weakness (often with CPK elevations) and do not support the specific scenario of aches without weakness and do not describe 'dark urine' in that context.
Lipitor can cause mild digestive symptoms such as nausea, constipation, and diarrhea.
No nausea/constipation/diarrhea adverse reaction content is present in the provided label excerpts.
Lipitor can cause headache or general tiredness.
Fatigue is mentioned in postmarketing experience, but headache is not present in the provided excerpts.
New or worse symptoms can show up after starting Lipitor after a gap.
No label language in the provided excerpts addresses symptom timing after a treatment gap.
Muscle-related issues from Lipitor can occur at any time.
The provided excerpts do not include an 'at any time' timing statement.
Many people notice muscle-related symptoms within weeks to months after starting or changing the Lipitor dose.
The provided excerpts include monitoring during initial months and around dose titration but do not provide a general statement that 'many people' experience symptoms within 'weeks to months.'
Liver-related symptoms from Lipitor are less common and can develop over time.
The provided excerpts discuss biochemical abnormalities, incidence, and that liver enzyme changes generally occur in the first 3 months; they do not describe 'liver-related symptoms' developing over time or 'less common' in symptom terms.
For severe muscle symptoms (especially with weakness or dark urine) associated with Lipitor, urgent care should be sought.
The provided excerpts do not instruct patients to seek 'urgent care' and do not mention 'dark urine' as a cue for seeking care.
For trouble breathing, swelling, or jaundice, urgent care should be sought.
The provided excerpts include serious hypersensitivity reactions (e.g., anaphylaxis/angioneurotic edema) and jaundice but do not provide 'urgent care' instructions.
Clinicians may adjust the dose or switch statins in response to symptoms related to Lipitor.
The provided excerpts support discontinuation and dose reduction/withdrawal (liver or muscle) but do not explicitly state 'switch statins.'
Contradictions
Important Omissions
Explicit boxed warning status/boxed content and contraindication details were not discussed (e.g., hypersensitivity contraindication is present in excerpts only as a section heading/text, and other contraindications like active liver disease are present in provided excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While major on-label safety themes are present, unsupported symptom specificity and non-label 'urgent care' directives could mislead patients about hallmark signs and appropriate action timing. Most interaction and monitoring statements are aligned.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Multiple symptom-specific and action/timing statements are not supported by the provided label excerpts (notably 'dark/cola-colored urine' and 'urgent care' instructions, plus several liver symptom attributions and generalization about when symptoms occur).
Suggested Improvement
Restrict patient-facing symptom and action language to what is supported in the provided label sections (e.g., muscle pain/tenderness/weakness and CPK-related guidance; liver function testing and jaundice occurrence), and remove or rephrase unsupported symptom cues ('dark/cola-colored urine' as a sign) and unsupported instructions ('urgent care should be sought') unless directly supported in the label text provided.